In conclusion, the results of this work highlight limitations in the current practice toward the treatment of FLT3-ITD positive patients affected by AML and open-up opportunities for additional, more effective and patient-specific therapeutic strategies. This evidence concerns the gene FLT3 and acute myeloid leukemia.